Whalesbook
Dekho bhai, hua yeh hai ki Ajanta Pharma ke Paithan, Maharashtra waale manufacturing plant mein 13 se 21 April tak US FDA ki team aayi thi inspection ke liye. Is inspection ke baad, unhone plant mein 5 alag-alag points note kiye hain, jo ek Form 483 par likhe gaye hain. Company ne confirm kiya hai ki wo deadline ke andar FDA ko apna detailed response submit karenge.
Is news ke baad, Ajanta Pharma ka stock 22 April ko practically flat band hua, sirf 0.16% neeche ₹2,786.80 par. Aur agar is saal ki baat karein toh stock ab tak lagbhag 5% gir chuka hai. Ye regulatory khabar pharma sector mein pehle se chal rahe caution ko aur thoda badha rahi hai.
Asal mein, poore Indian pharma sector par abhi global regulatory nazar rakhi hui hai, USFDA ne foreign inspections kaafi badha di hain. Aisa hi kuch hua tha Cipla ke saath bhi, jinke Goa facility mein 2 Form 483 observations aayi thi. Abhi Ajanta Pharma ka TTM P/E ratio lagbhag 34.36 chal raha hai, jo industry average 25.29 aur company ke khud ke 10-saal ke median 27.11 se zyada hai. Compare karein toh Lupin ka P/E 22.80, Dr. Reddy's ka 17.29, Divi's Labs ka 67.40, aur Laurus Labs ka 72.28 hai. Toh Ajanta Pharma ka valuation competitors se zyada lag raha hai, jiska matlab hai ki agar regulatory issues aaye toh stock par pressure zyada aa sakta hai.
Pehle bhi Ajanta Pharma ne FDA inspections handle ki hain. September 2022 mein Dahej plant mein 2 observations aayi thi, jisse stock thoda gira tha, par June 2023 mein wahi plant clear ho gaya tha aur stock ne gain kiya tha. Yeh jo ab tak 5% ka drop dikh raha hai, woh shayad isi risk pricing ka hissa hai. Analysts waise toh abhi bhi 'Buy' rating de rahe hain aur average target ₹3,203 ke aas paas hai, lekin yeh observations aane ke baad shayad kuch analysts apne forecasts revise karein.
Ab sabki nazar Ajanta Pharma ke response par rahegi. Dekhna hoga ki wo kitni jaldi aur kitne effective tareeke se un 5 observations ko theek karte hain. Agar issues badh gaye ya exports mein dikkat aayi toh company ki earnings par impact pad sakta hai, khaas kar US market se revenue ko lekar. Ye sab factors investors ke liye important honge watch karne ke liye.